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Plasma Thrombin Activatable Fibrinolysis Inhibitor
Levels in Behçet’s Disease
Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behçet’s disease (BD) are still
not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on
endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis
inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic
disorders. We studied plasma TAFI levels in BD in comparison with healthy controls.
Materials and Methods: Twenty-three patients with BD (mean age: 38.3 ± 10.83, M/F: 5/18) diagnosed
according to the criteria of the International Study Group and 20 healthy volunteers (mean age: 38.05 ± 6.29,
M/F: 9/11) were enrolled in this study. Patients with liver or renal disease, diabetes mellitus, coronary artery
disease, hemophilia, antiphospholipid antibody positivity or using oral contraceptive drugs were excluded from
the study. Plasma TAFI levels were determined by using an ELISA test.
Results: The mean TAFI antigen levels were 8.40 ± 1.81µg/ml in BD patients and 7.30 ± 0.64 µg/ml in
healthy volunteers. A statistically significant difference was found between TAFI antigen levels of these two
groups (P = 0.01).
Conclusions: TAFI antigen levels were found to be increased in BD, regardless of thrombotic events. To clarify
the exact role of TAFI in thrombotic complications of the disease, future studies including more patients with
and without thrombosis are needed.
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Behçet Hastal›¤›nda Plazma Trombin ile Aktive Edilebilen
Fibrinoliz ‹nhibitör (TAF‹) Seviyesi
Amaç: Behçet hastal›¤›nda görülen trombotik komplikasyonlar›n patogenetik mekanizmalar› henüz net
de¤ildir. Patogenezi endotel disfonksiyonu, koagulasyon ve fibrinolitik sistemlerindeki bozukluklar ile
aç›klayabilmek için pek çok hemostatik parametre çal›ﬂ›lm›ﬂt›r. Trombin ile active edilebilen fibrinoliz inhibitörü
(TAF‹) plazmin oluﬂumunu ve fibrinolizi inhibe eden, trombotik bozukluklarda etkisi son y›llarda keﬂfedilmiﬂ
bir risk faktörüdür. Bu çal›ﬂmada Behçet hastal›¤›nda ve kontrol grubunda TAF‹ plazma seviyeleri
araﬂt›r›lm›ﬂt›r.
Yöntem ve Gereç: Erkek kad›n oran› 5/18, ortalama yaﬂlar› 38.3 ± 10.83 olan 23 Behçet hastas› (Uluslararas›
çal›ﬂma kriterlerine göre tan› alm›ﬂ) ile, erkek kad›n oran› 9/11 ortalama yaﬂlar› 38.05 ± 6.29 olan sa¤l›kl›
kontroller çal›ﬂmaya al›nd›. Karaci¤er, böbrek hastal›¤›, diyabeti, koroner hastal›¤›, antifosfolipid antikor
pozitifli¤i olan, oral kontraseptif kullanan hastalar çal›ﬂma d›ﬂ› b›rak›ld›. Plazma TAF‹ seviyesi EL‹ZA testi
kullan›larak ölçüldü.
Bulgular: TAF‹ antijen plazma seviyeleri Behçet hastalar›nda 8.40 ± 1.81µg/ml, sa¤l›kl› gönüllülerde 7.30 ±
0.64 µg/ml olarak bulundu. ‹ki grup aras›nda TAF‹ seviyeleri aç›s›ndan istatistiksel anlaml› fark mevcuttu
(P = 0.01).
Sonuç: Trombotik olay varl›¤›ndan ba¤›ms›z olarak Behçet hastal›¤›nda TAF‹ antijen seviyesi yüksekti. Ancak
hastal›¤›n etiyolojisinde TAF‹’nin yerinin daha net anlaﬂ›labilmesi için trombotik komplikasyonu olan grubun da
bulundu¤u, daha fazla say›da olgu içeren çal›ﬂmalara gerek vard›r.
Anahtar Sözcükler: Behçet Hastal›¤›, TAF‹, koagulasyon, fibrinoliz

inci074@yahoo.com
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Introduction

Materials and Methods

Behçet’s disease (BD), firstly described by Hulusi
Behçet in 1937, is a chronic multisystem disorder of
unknown etiology. The disease is characterized by
recurrent aphthous oro-genital ulcers, ocular
inflammations and skin lesions. The main
histopathology found in BD is vasculitis involving all
types and sizes of blood vessels (1). Systemic vascular
lesions include arterial aneurysms, small vessel
vasculitis, and arterial and venous thrombosis (2).
Thrombotic complications have been reported in
approximately 12-40% of patients with this disease.
The precise pathogenetic mechanisms causing
thrombotic complications are still not known (1).
Endothelial dysfunction due to vascular inflammation is
considered to be an important factor of thrombosis.
Endothelial injury itself cannot be the only factor for
development of thrombosis, because other vasculitic
syndromes do not increase the risk of thrombosis (3).
In order to explain the pathogenesis with coagulation
induction or a defective fibrinolysis superimposed on
endothelial dysfunction, various hemostatic parameters
were studied. Protein C, protein S and antithrombin
(AT) deficiencies, presence of antiphospholipid
antibodies and factor V Leiden and prothrombin
20210A mutations, and high homocysteine level have
been considered to be related with hypercoagulable
state in BD (4-9). Low values of plasminogen activator
activity, impaired fibrinolytic kinetics or relative
hypofibrinolytic state were also suggested in the
prothrombotic state of BD (10-12).

Twenty-three patients with BD (mean age: 38.3 ±
10.83, M/F: 5/18) diagnosed according to the Criteria of
the International Study Group and 20 healthy volunteers
(mean age: 38.05 ± 6.29, M/F: 9/11) were enrolled in
this study. Informed consent was obtained from all
individuals. Patients with liver or renal disease, diabetes
mellitus, coronary artery disease, hemophilia,
antiphospholipid antibody positivity or using oral
contraceptive drugs were excluded from the study.

Thrombin activatable fibrinolysis inhibitor (TAFI) is a
novel risk factor for thrombotic disorders. It is a plasma
procarboxypeptidase B-like proenzyme (zymogen)
synthesized in the liver. TAFI is converted to an active
carboxypeptidase (TAFI a) enzyme to downregulate
plasmin generation and fibrinolysis (13). The role of TAFI
in thrombotic events has been studied. Increased plasma
TAFI antigen levels were found to be related to
thrombotic tendency in the literature (14-18).
Considering the role of TAFI in downregulation of
fibrinolysis, we aimed to investigate the relationship
between plasma TAFI levels and BD.
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The patients were evaluated with respect to current
clinical activity. They were included in the active group if
they had at least two of the following clinical findings:
mouth ulcers, genital ulceration, active uveitis, recent
arthritis, thrombophlebitis and large vessel involvement.
Blood Collection
Blood samples were obtained from antecubital vein
into citrated tubes (trisodium-citrate 0.129 mol/L, whole
blood ratio 1:9) and centrifuged at 1500 xg for 15 min.
All plasma samples were then divided into aliquots and
frozen at -80 ºC until test performance. At the same time
blood samples were obtained, whole blood count, liver
function tests, renal function tests, erythrocyte
sedimentation rate (ESR), and serum C-reactive protein
(CRP) were also studied in each subject.
TAFI Antigen Assay
TAFI antigen was determined using an ELISA kit from
Affinity Biologicals Inc, Ontario, Canada, which consists of
affinity purified sheep anti-TAFI IgG capture antibody and
pre-diluted HRP-conjugated affinity purified sheep antiTAFI detecting antibody. This test measures total TAFI
antigen, including pro-TAFI (procarboxypeptidase U),
TAFI (carboxypeptidase U), and TAFIi (inactivated
carboxypeptidase U). All necessary buffers and reagents
were prepared according to manufacturer’s instructions
and all samples were studied as soon as they were thawed
at room temperature. Test plasma samples were diluted
1/200. All results were given as µg/ml.
Statistics:
All data were collected at ‘Excel XP for Windows’
program and statistical analysis was performed using the
SPSS 10.0 statistical package. Mann-Whitney U test was
used to compare the two groups, and all p-values were
two-sided. A value of P < 0.05 was considered as
significant.
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Results

Discussion

Demographic data and main clinical features of the
patients and healthy volunteers are given in Table 1 and
Table 2. The two groups were sex-matched (P = 0.104)
and there was also no significant difference between the
two groups according to age. The characteristic features
of the disease in BD patients are also given in Table 1 (at
the time of diagnosis and at the time of the study).
Thirteen (56.5%) patients were clinically active and none
of the patients had deep vein thrombosis (DVT) at the
time of the study. Only two (8.7%) patients who were
clinically inactive had a history of DVT.

The mean TAFI antigen levels were also studied
according to activity of the disease. Although it seems
that TAFI antigen levels were higher in patients with
active disease compared with the inactive group (9.04 ±
1.61 µg/ml vs 7.56 ± 1.78 µg/ml) (Figure 2), there was
no significant difference between the two disease groups
(P = 0.088).

TAFI plays an important role in hemostatic balance
between coagulation and fibrinolysis and affects clot
stability (18,19). It is activated by many factors including
thrombin, plasmin and trypsin. After activation, it is
converted to an active carboxypeptidase (TAFIa) enzyme.
TAFIa removes the carboxy-terminal lysyl and arginyl
residues of partially degraded fibrin, which serve as
plasminogen binding sites, and plasminogen activation is
inhibited. Hence, TAFIa is a potent inhibitor of tissue
plasminogen activator-induced fibrinolysis (19). The role
of TAFI has been studied in many diseases to explain
disease pathology (14-16,20). Due to thrombotic
tendency in BD, many factors that may underlie this
pathology were investigated (4-11). Deficiencies in
protein C, protein S, and antithrombin or the presence of
antiphospholipid antibodies and factor V Leiden and
prothrombin 20210A mutations have been considered.
While some studies found an association between these
abnormalities and thrombosis in BD (4-10), others did
not (21,22). In light of all these literatures, questions
remain regarding the cause of the majority of the
thrombosis in this disease, so one may speculate that
TAFI as a novel candidate may also be involved in the
pathology of thrombotic events in BD.

Table 1. Activity parameters in patients with Behçet’s disease.

Table 2. Characteristics of patients and healthy volunteers.

The mean TAFI antigen levels were 8.40 ± 1.81 µg/ml
in BD patients and 7.30 ± 0.64 µg/ml in healthy
volunteers. A statistically significant difference was found
between TAFI antigen levels of the two groups (P = 0.01)
(Figure 1).

BEHÇET’S PATIENTS
(n: 23)
Female/Male

5/18

Age

Behçet’s Patients
n:23

Control Group
n:20

38.3 ± 10.83

38.05 ± 6.29

5/18

9/11

Oral ulcer

17/23(73.9%)

Female/Male

Genital ulcer

5/23 (21.7%)

Duration of disease (month)

8.62 ± 9.65

Skin lesions

10/23 (43.5%)

Hb (g/dl)

14.33 ± 1.56

3/23 (13.0%)

WBC (x109/L)

Arthritis
Eye lesion
Pathergy positivity
ENLL

2/23 (8.7%)
3/9 (14 cases missing)
2/23 (8.7%)

7.62 ± 1.85

9

289.36 ± 76.39

Erythrocyte sedimentation
rate (mm/hr)

18.5 ± 20.13

C-reactive protein (CRP)

8.69 ± 15.71

Platelet (x10 /L)

(erythema nodosum-like lesion)
Superficial thrombophlebitis
Deep vein thrombosis
Clinical activity

1/23 (4.3%)
0/23
13/23 (56.5%)
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Figure 1. Thrombin activatable fibrinolysis inhibitor antigen levels in
patients and volunteers.

Figure 2. Thrombin activatable fibrinolysis inhibitor antigen levels in
active and inactive Behçet’s patients.

The first study about TAFI levels in BD was made by
Donmez et al. (23). The main aim of their study was to
assess plasma TAFI levels in this disease, compared with
healthy controls, and BD subgroups with and without
thrombosis. They evaluated TAFI variations in 105 BD
(55 with thrombosis, 50 without thrombosis, 29
clinically active, 76 clinically inactive) patients and 53
healthy volunteers. They found that plasma TAFI levels in
all subgroups of BD were significantly higher than in
healthy controls; however, there was no positive
correlation of TAFI antigen levels with thrombosis or with
clinical activity.

sex differences between the two groups. TAFI antigen
levels in patients with BD were significantly higher than in
healthy volunteers (P = 0.01).

In our study, we enrolled 23 patients with BD and 20
healthy volunteers. 56.5% of patients were clinically
active at the time of clinical assessment. They had no
thrombotic events at the time of the study. Since during
thrombotic events, coagulation and the fibrinolytic
system would be active and affect the interpretations of
the results, we did not include the patients with
thrombosis in this study. But 8.7% of patients (2
patients) had DVT history. The number of patients in this
group was not enough to make a comment on the
relationship between TAFI levels and BD subgroups (withwithout thrombosis). There were no significant age or
270

The mean TAFI antigen levels were also studied
according to disease activity because TAFI is accepted as
an acute phase reactant. TAFI antigen levels were found
higher in patients with active disease compared with the
inactive group, but the difference was not significant (P =
0.088). This may be due to the small numbers of the
study subgroups.
In this study, we did not evaluate other fibrinolytic
parameters in BD. We only investigated whether or not
TAFI was involved in thrombotic tendency in BD. High
TAFI levels, which reached a level of significance, may
support this idea. In the previous study, which was the
first case-control study to show higher TAFI levels in the
disease, subgroups with and without thrombosis were
studied and no differences between them were
determined. In our study, there were no such subgroups
for comparison. But it is known that BD itself has
thrombotic complications. The patients may manifest
such complications in the future. They are still followed at
regular intervals. Sole measurement of plasma TAFI
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antigen levels but not functional TAFI activity is also a
limitation of our study.
In conclusion, many factors have a role in thrombotic
tendency in BD. TAFI antigen levels were found to be
increased in BD, regardless of thrombotic events, in this
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study. To clarify the exact role of TAFI in thrombotic
complications of the disease, future studies including
more patients with and without thrombosis are needed,
and functional TAFI activity and TAFI gene
polymorphisms need to be evaluated as well.
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